S&P 500   4,586.91 (+0.83%)
DOW   36,140.09 (+0.24%)
QQQ   391.25 (+1.61%)
AAPL   194.38 (+1.07%)
MSFT   371.02 (+0.60%)
META   327.48 (+3.16%)
GOOGL   137.30 (+5.60%)
AMZN   147.06 (+1.76%)
TSLA   241.67 (+0.96%)
NVDA   465.04 (+2.20%)
NIO   7.52 (-2.97%)
BABA   72.27 (+1.09%)
AMD   128.09 (+9.65%)
T   17.08 (+0.83%)
F   10.84 (+1.40%)
MU   74.17 (+1.42%)
CGC   0.73 (+4.19%)
GE   119.03 (-0.65%)
DIS   92.71 (+1.32%)
AMC   6.88 (+1.33%)
PFE   28.80 (+0.03%)
PYPL   58.85 (-1.14%)
XOM   98.35 (-0.77%)
S&P 500   4,586.91 (+0.83%)
DOW   36,140.09 (+0.24%)
QQQ   391.25 (+1.61%)
AAPL   194.38 (+1.07%)
MSFT   371.02 (+0.60%)
META   327.48 (+3.16%)
GOOGL   137.30 (+5.60%)
AMZN   147.06 (+1.76%)
TSLA   241.67 (+0.96%)
NVDA   465.04 (+2.20%)
NIO   7.52 (-2.97%)
BABA   72.27 (+1.09%)
AMD   128.09 (+9.65%)
T   17.08 (+0.83%)
F   10.84 (+1.40%)
MU   74.17 (+1.42%)
CGC   0.73 (+4.19%)
GE   119.03 (-0.65%)
DIS   92.71 (+1.32%)
AMC   6.88 (+1.33%)
PFE   28.80 (+0.03%)
PYPL   58.85 (-1.14%)
XOM   98.35 (-0.77%)
S&P 500   4,586.91 (+0.83%)
DOW   36,140.09 (+0.24%)
QQQ   391.25 (+1.61%)
AAPL   194.38 (+1.07%)
MSFT   371.02 (+0.60%)
META   327.48 (+3.16%)
GOOGL   137.30 (+5.60%)
AMZN   147.06 (+1.76%)
TSLA   241.67 (+0.96%)
NVDA   465.04 (+2.20%)
NIO   7.52 (-2.97%)
BABA   72.27 (+1.09%)
AMD   128.09 (+9.65%)
T   17.08 (+0.83%)
F   10.84 (+1.40%)
MU   74.17 (+1.42%)
CGC   0.73 (+4.19%)
GE   119.03 (-0.65%)
DIS   92.71 (+1.32%)
AMC   6.88 (+1.33%)
PFE   28.80 (+0.03%)
PYPL   58.85 (-1.14%)
XOM   98.35 (-0.77%)
S&P 500   4,586.91 (+0.83%)
DOW   36,140.09 (+0.24%)
QQQ   391.25 (+1.61%)
AAPL   194.38 (+1.07%)
MSFT   371.02 (+0.60%)
META   327.48 (+3.16%)
GOOGL   137.30 (+5.60%)
AMZN   147.06 (+1.76%)
TSLA   241.67 (+0.96%)
NVDA   465.04 (+2.20%)
NIO   7.52 (-2.97%)
BABA   72.27 (+1.09%)
AMD   128.09 (+9.65%)
T   17.08 (+0.83%)
F   10.84 (+1.40%)
MU   74.17 (+1.42%)
CGC   0.73 (+4.19%)
GE   119.03 (-0.65%)
DIS   92.71 (+1.32%)
AMC   6.88 (+1.33%)
PFE   28.80 (+0.03%)
PYPL   58.85 (-1.14%)
XOM   98.35 (-0.77%)

Alnylam Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNY)

$176.45
+1.43 (+0.82%)
(As of 02:20 PM ET)
Compare
Today's Range
$174.39
$177.77
50-Day Range
$151.41
$178.96
52-Week Range
$148.10
$242.97
Volume
252,747 shs
Average Volume
671,963 shs
Market Capitalization
$22.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$233.00

Alnylam Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.68 Rating Score
Upside/​Downside
31.5% Upside
$233.00 Price Target
Short Interest
Healthy
4.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.99mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.74) to ($5.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

133rd out of 958 stocks

Pharmaceutical Preparations Industry

31st out of 393 stocks


ALNY stock logo

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Stock Price History

ALNY Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Oppenheimer Keeps Their Hold Rating on Teva Pharmaceutical (TEVA)
Alnylam Pharmaceuticals Inc. Q3 Earnings Summary
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
2,002
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$233.00
High Stock Price Target
$395.00
Low Stock Price Target
$143.00
Potential Upside/Downside
+33.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
19 Analysts

Profitability

Net Income
$-1,131,160,000.00
Pretax Margin
-29.17%

Debt

Sales & Book Value

Annual Sales
$1.04 billion
Book Value
($1.29) per share

Miscellaneous

Free Float
123,736,000
Market Cap
$21.96 billion
Optionable
Optionable
Beta
0.50

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Tuesday, November 28, 2023 at 10:13 PM.

Pros

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Strong pipeline of investigational RNAi therapeutics targeting various diseases, including genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.
  • Marketed products such as ONPATTRO, GIVLAARI, and OXLUMO have shown promising results in treating specific conditions, providing potential revenue streams.
  • Strategic collaborations with Regeneron Pharmaceuticals, Sanofi Genzyme, and other companies enhance the company's research and development capabilities and market reach.
  • Ongoing clinical trials for products like givosiran, patisiran, and vutrisiran offer potential for future product approvals and market expansion.
  • Recent positive developments and partnerships indicate a strong growth trajectory for the company.

Cons

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which may impact the company's ability to bring products to market.
  • Investing in biopharmaceutical companies carries inherent risks, including clinical trial failures, regulatory setbacks, and intellectual property disputes.
  • Market volatility and economic uncertainties can affect the company's stock price and overall financial performance.
  • Dependency on successful product launches and commercialization efforts for revenue generation.
  • Potential impact of healthcare reforms and changes in reimbursement policies on the company's financials.














ALNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price target for 2024?

19 brokers have issued 1 year target prices for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $143.00 to $395.00. On average, they predict the company's stock price to reach $233.00 in the next twelve months. This suggests a possible upside of 31.5% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2023?

Alnylam Pharmaceuticals' stock was trading at $237.65 at the beginning of 2023. Since then, ALNY stock has decreased by 25.4% and is now trading at $177.19.
View the best growth stocks for 2023 here
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of ($1.61) by $2.76. The biopharmaceutical company had revenue of $750.53 million for the quarter, compared to analyst estimates of $406.14 million.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.51%), Wellington Management Group LLP (5.13%), Northern Trust Corp (0.64%), Legal & General Group Plc (0.63%), Ameriprise Financial Inc. (0.56%) and Massachusetts Financial Services Co. MA (0.55%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALNY) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -